The purpose of the proposed investigation is to carry out a pilot study of add-on perampanel
(Fycompa) in women with perimenstural (C1) catamenial epilepsy. Perampanel, a noncompetitive
AMPA receptor antagonist, is uniquely positioned to decrease progesterone receptor mediated
excitotoxicity. This mechanism of action would allow a novel use of perampanel as an
effective treatment of C1 catamenial epilepsy.